Drug-induced liver injury (DILI) is one of the most serious safety liabilities in pharmaceutical development. It is the leading cause of post-marketing drug withdrawals, accounts for more than 50% of acute liver failure cases in Western countries, and has ended the development programmes of numerous promising drug candidates that passed all standard preclinical safety tests. Understanding why DILI is so difficult to predict — and what the best available tools are to detect it early — is a core competency for any DMPK or drug safety team.

The bile salt export pump (BSEP, ABCB11) is at the centre of the most well-characterised mechanistic pathway to drug-induced cholestatic liver injury. A study published in ACS Medicinal Chemistry Letters in September 2024 by Li et al. demonstrates new high-throughput mass spectrometry approaches to BSEP inhibition testing — and validates them directly against the membrane vesicle assay that remains the regulatory reference method.

What BSEP Does — and Why Inhibiting It Causes Liver Injury

BSEP is an ATP-binding cassette (ABC) efflux transporter expressed almost exclusively on the canalicular membrane of hepatocytes. Its physiological role is specific and critical: it actively exports bile salts from hepatocytes into the bile canaliculi, providing the primary driving force for bile formation. The bile salt pool undergoes enterohepatic circulation approximately six to eight times per day, with daily bile salt excretion of around 20–40 grams.

When a drug inhibits BSEP, bile salts accumulate in the hepatocyte. Above a threshold concentration, bile salts become cytotoxic — disrupting mitochondrial function, activating apoptotic pathways, and causing hepatocellular damage. The clinical presentation is cholestatic or mixed hepatocellular-cholestatic liver injury. Several high-profile drug withdrawals have been mechanistically linked to BSEP inhibition, including troglitazone, bosentan, and nefazodone.

The Standard Method: Membrane Vesicle Assay

The established in vitro method for quantifying BSEP inhibition is the membrane vesicle assay using inside-out membrane vesicles from cells overexpressing human BSEP — typically HEK293 or Sf9 insect cells. In this assay:

1. Inside-out vesicles are incubated with ATP and a radiolabelled or MS-detectable bile salt substrate — most commonly taurocholic acid (TCA)
2. The drug candidate is added at multiple concentrations
3. ATP-dependent TCA uptake into the vesicle lumen is measured
4. Inhibition of uptake relative to vehicle control gives the IC₅₀
5. An IC₅₀ above 25–50 µM is generally considered acceptable; below 10 µM raises a DILI flag requiring follow-up

This method is accepted by both the FDA (2020 DDI Guidance) and EMA (2012 DDI Guideline) as the standard approach for BSEP inhibition characterisation in IND-enabling DMPK studies. It does not require radioactivity when a mass spectrometry readout is used — and this is precisely where the 2024 Li et al. study makes its contribution.

The 2024 Innovation: High-Throughput MS-Based BSEP Testing

Traditional LC-MS-based BSEP vesicle assays are analytically rigorous but operationally limiting. Sample preparation steps — protein precipitation, centrifugation, solvent evaporation — add time and complexity. A typical 96-well plate run takes hours. For drug discovery campaigns screening hundreds of compounds, this throughput bottleneck is a real constraint.

The Li et al. 2024 study in ACS Medicinal Chemistry Letters demonstrates two approaches that address this directly:

Both high-throughput methods were validated against the standard LC-MS approach using 96 drug candidates and BSEP vesicles measuring taurocholic acid (TCA) transport inhibition. The key finding: IC₅₀ values obtained by RapidFire-MS and DESI-MS correlated strongly with LC-MS reference values, demonstrating that throughput can be dramatically increased without compromising data quality.

BSEP in the Regulatory Context — FDA and EMA Requirements

Both the FDA 2020 Drug Interaction Guidance and the EMA 2012 DDI Guideline address BSEP testing. The FDA guidance is explicit: BSEP inhibition should be evaluated for all new molecular entities (NMEs) during IND-enabling studies. The recommended in vitro method is the membrane vesicle assay.

The Dual Liability Concept — Why BSEP Alone is Not the Full Picture

An important refinement from the literature: BSEP inhibition alone is a necessary but not always sufficient predictor of clinical DILI. The dual liability concept — simultaneous inhibition of BSEP and mitochondrial function — has emerged as a stronger predictor of severe hepatotoxicity than BSEP IC₅₀ alone.

Additionally, dual inhibition of BSEP and MRP2 or MRP3 impairs the compensatory bile acid efflux pathways that partially protect hepatocytes when BSEP is inhibited. This is why a complete DMPK transporter panel — covering not only BSEP but also MRP2, MRP3, MRP4, and P-gp — provides a more complete DILI risk profile than BSEP testing in isolation.

Choosing the Right BSEP Vesicle Kit

The Li et al. 2024 study reinforces what experienced DMPK scientists already know: the quality of the membrane vesicle preparation is the most critical variable in any BSEP assay format. Vesicles with low BSEP expression, poor inside-out orientation, or inconsistent lot-to-lot activity produce unreliable IC₅₀ values regardless of the detection method.

Key parameters to evaluate when selecting a BSEP vesicle kit: